author-photo

Nicolas Leupin

Celgene

8

Papers

185

Citations

Citation Trend

Filter By

Papers (7) Sort By

Journal Conference Others

Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans

2018 Journal of Clinical Investigation
Show All
- Source
- Cite
- Save
Citations (72)
Phase I dose-escalation study of the anti-CD70 antibody ARGX-110 in advanced malignancies

2017 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (23)
CD70 EXPRESSION IN CUTANEOUS T CELL LYMPHOMA (CTCL) PATIENTS AND MECHANISMS OF ACTION OF ARGX-110 IN SKIN: HISTOPATHOLOGICAL AND CLINICAL DATA

2017 Hematological Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Updated Outcomes and Impact of Age With Lenalidomide and Low-Dose Dexamethasone or Melphalan, Prednisone, and Thalidomide in the Randomized, Phase III FIRST Trial.

2016 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (59)
Impact of Response in Patients (Pts) With Stem Cell Transplant (SCT)-Ineligible Newly Diagnosed Multiple Myeloma (NDMM) Treated With Continuous Lenalidomide + Low-Dose Dexamethasone (Rd) in the FIRST Trial

2015 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (2)
Impact of Response Quality on Survival Outcomes in Transplant-Ineligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): Results from the First Trial

2014 Blood
Show All
- Source
- Cite
- Save
Citations (1)
The STRATUS trial (MM-010): A single-arm phase 3b study of pomalidomide plus low-dose dexamethasone (POM + LoDEX) in refractory or relapsed and refractory multiple myeloma.

2014 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (2)